Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Jong Kyun Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1298-0494; OpenAlex author ID A5021583238. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2012: 2 papers · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 2 papers

Papers 19

  1. Artificial Intelligence-Powered Spatial Analysis of Immune Phenotypes in Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2025.1999↗
  2. Skeletal Muscle Index Changes on Locoregional Treatment Application After FOLFIRINOX and Survival in Pancreatic Cancer. Co-author DOI 10.1002/jcsm.13643↗
  3. Serum trace elements during treatment in pancreatic cancer patients and their associations with cancer prognosis. First author DOI 10.1016/j.clnu.2024.04.012↗
  4. Impact and optimal timing of local therapy addition in borderline resectable or locally advanced pancreatic cancer after FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.ctro.2024.100732↗
  5. Establishment of a patient-specific avatar organoid model derived from EUS-guided fine-needle biopsy for timely clinical application in pancreatic ductal adeno… Co-author DOI 10.1016/j.gie.2024.02.021↗
  6. Lysosomal Storage Dysfunction, a Germline Variants Affecting Pancreatic Ductal Adenocarcinoma Development and Progression Co-author DOI 10.1101/2023.02.15.23286007↗
  7. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-023-04549-x↗
  8. Lysosomal Storage Dysfunction, a Germline Variants Affecting Pancreatic Ductal Adenocarcinoma Development and Progression Co-author DOI 10.21203/rs.3.rs-2578124/v1↗
  9. Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2021.101321↗
  10. The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer. Co-author DOI 10.3390/cancers14194556↗
  11. Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.5009/gnl19011↗
  12. Preoperative EUS-guided FNA: effects on peritoneal recurrence and survival in patients with pancreatic cancer. Co-author DOI 10.1016/j.gie.2018.06.024↗
  13. KRAS mutation analysis of washing fluid from endoscopic ultrasound-guided fine needle aspiration improves cytologic diagnosis of pancreatic ductal adenocarcino… Co-author DOI 10.18632/oncotarget.13864↗
  14. Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. Co-author DOI 10.18632/oncotarget.17463↗
  15. Postoperative prognosis prediction of pancreatic cancer with seven microRNAs. First author DOI 10.1097/mpa.0000000000000346↗
  16. Clinicoradiologic characteristics and outcomes of metastatic cancer to the pancreas and double primary pancreatic cancer. Co-author DOI 10.1016/j.clinre.2012.05.013↗
  17. [New-onset diabetes as an early sign of pancreatic cancer]. First author DOI 10.4166/kjg.2013.62.5.263↗
  18. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review. Co-author DOI 10.1097/coc.0b013e31821a83d7↗
  19. The value of positron emission tomography/computed tomography for evaluating metastatic disease in patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318252f4f5↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kyu Taek Lee · 15 shared papers, 2012–2025 · strength 1.76
  2. Joo Kyung Park · 12 shared papers, 2017–2025 · strength 1.70
  3. Kwang Hyuck Lee · 10 shared papers, 2012–2024 · strength 0.94
  4. Hye Min Kim · 6 shared papers, 2022–2025 · strength 0.91
  5. Jin Seok Heo · 5 shared papers, 2017–2025 · strength 0.76
  6. In Woong Han · 4 shared papers, 2022–2025 · strength 0.70
  7. Sang Hyun Shin · 4 shared papers, 2022–2025 · strength 0.70
  8. Young Hoon Choi · 4 shared papers, 2023–2025 · strength 0.60
  9. Kee‐Taek Jang · 6 shared papers, 2012–2025 · strength 0.59
  10. Jin Ho Choi MD · 3 shared papers, 2024–2025 · strength 0.55
  11. Hee Chul Park · 4 shared papers, 2012–2025 · strength 0.54
  12. Joon Oh Park · 4 shared papers, 2012–2025 · strength 0.54
  13. Jeong Il Yu · 3 shared papers, 2022–2025 · strength 0.52
  14. Soo‐Youn Lee · 2 shared papers, 2017–2024 · strength 0.42
  15. Youngil Koh · 3 shared papers, 2023 · strength 0.42
  16. Hyung Rae Kim · 3 shared papers, 2023 · strength 0.42
  17. Sung‐Soo Yoon · 3 shared papers, 2023 · strength 0.42
  18. Daechan Park · 3 shared papers, 2023 · strength 0.42
  19. Kangpyo Kim · 2 shared papers, 2024–2025 · strength 0.38
  20. Ji Hye Min · 2 shared papers, 2024–2025 · strength 0.38
  21. Jung Yong Hong · 2 shared papers, 2024–2025 · strength 0.38
  22. Hongbeom Kim · 2 shared papers, 2025 · strength 0.38
  23. Kyunga Kim · 2 shared papers, 2024–2025 · strength 0.37
  24. Jee Ah Kim · 1 shared paper, 2024 · strength 0.36
  25. Jin‐Young Jang · 2 shared papers, 2023 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.